Search results for " non-steroidal"

showing 10 items of 281 documents

Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report

2013

Summary What is known and objective Safety of the anti-inflammatory drug flurbiprofen is comparable with that of other non-steroidal anti-inflammatory drugs of the propionic acid class, which are commonly associated with gastrointestinal and renal side effects. Here we report a case of a fatal hypersensitivity reaction to an oral spray of flurbiprofen taken for sore throat. Case summary A 29-year-old man came to the emergency care unit reporting sore throat with an intense burning sensation associated with fever. Pharyngotonsillitis was diagnosed, and local treatment with oral flurbiprofen spray was prescribed. Immediately after using the spray, the patient experienced a severe reaction cha…

AdultMaleoral sprayAllergyAdministration TopicalFlurbiprofenAdministration OralFatal hypersensitivity reaction; oral spray; flurbiprofenadverse Effect; adverse reaction; anti inflammatory; fatal reaction; flurbiprofen; hypersensitivity; NSAID; pharmacovigilance; sprayDrug HypersensitivitySettore MED/43 - Medicina LegalemedicineMaculopapular rashSore throatHumansPharmacology (medical)Fatal hypersensitivity reactionCause of deathPharmacologyAsphyxiabusiness.industryAnti-Inflammatory Agents Non-SteroidalPharyngitismusculoskeletal systemmedicine.diseaseflurbiprofenHypersensitivity reactionAnesthesiaItchinglipids (amino acids peptides and proteins)Oral Spraysmedicine.symptombusinessmedicine.drugJournal of Clinical Pharmacy and Therapeutics
researchProduct

Anti-Inflammatory Effects of Onions: Inhibition of Chemotaxis of Human Polymorphonuclear Leukocytes by Thiosulfinates and Cepaenes

1990

Seven different synthetic thiosulfinates, and cepaene- and/or thiosulfinate-rich onion extracts were found to inhibit in vitro the chemotaxis of human granulocytes induced by formyl-methionine-leucinephenylalanine in a dose-dependent manner and at a concentration range of 0.1–100 μ<i>M</i>. Diphenylthiosulfinate showed the highest activity and was found to be more active than prednisolone. The anti-inflammatory properties of onion extracts are related, at least in part, to the inhibition of inflammatory cell influx by thiosulfinates and cepaenes.

AdultNeutrophilsmedicine.drug_classImmunologyInflammationIn Vitro TechniquesBiologyGranulocyteAnti-inflammatoryAlliumMicrobiologymedicineHumansImmunology and AllergyDisulfidesThiosulfinatePlant ExtractsLiliaceaeAnti-Inflammatory Agents Non-SteroidalChemotaxisGeneral Medicinebiology.organism_classificationIn vitroN-Formylmethionine Leucyl-PhenylalanineChemotaxis Leukocytemedicine.anatomical_structureBiochemistrySulfoxidesImmunologymedicine.symptomInternational Archives of Allergy and Immunology
researchProduct

Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers

1993

Leflunomide (HWA 486), an isoxazol derivative, has been shown to be very effective in combating autoimmune diseases and transplantation rejection in a great number of animal models. The main metabolite of leflunomide, A77 1726, is a potent antiproliferative compound. To further elucidate this effect, lymphocytes of healthy human donors were cultured for 24, 48 or 72 h in the presence of PHA or immobilized anti-CD3 antibody. A77 1726 was added at concentrations between 10 and 100 microM. Flow cytometric evaluation of early activation or proliferation markers (IL-2 and transferrin receptors, respectively) showed that their expression was inhibited in a dose-dependent manner by A77 1726. Toget…

Adultmedicine.medical_specialtyAllergyToluidinesMetaboliteImmunologyHydroxybutyratesTransferrin receptorBiologyPharmacologyLymphocyte ActivationToxicologychemistry.chemical_compoundImmune systemInternal medicineNitrilesReceptors TransferrinmedicineHumansPharmacology (medical)PhytohemagglutininsLeflunomidePharmacologyAniline CompoundsAnti-Inflammatory Agents Non-SteroidalReceptors Interleukin-2Isoxazolesmedicine.diseaseRheumatologyTransplantationchemistryCrotonatesImmunologybiology.proteinAntibodyBiomarkersLeflunomidemedicine.drugAgents and Actions
researchProduct

2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint.

2021

Abstract Aim The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide from 2014, but in 2019 an update was published. Based on this algorithm, a Working Group (WG), including ESCEO members and Chinese experts, wished to see how the new ESCEO algorithm was perceived by Chinese experts in knee OA and how it was integrated into their clinical practice. Methods A WG was held between members of the international ESCEO task force and a group of Chinese experts. Results Non-pharmacological approach should be combined with pharmacological interventions. …

AgingChinaSymptomatic slow-acting drugs for osteoarthritisOsteoarthritis03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithm · ChinaConsensus Document030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryGeriatrics gerontologyTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis Kneemedicine.diseaseClinical PracticeAlgorithmPharmacological interventionsGeriatrics and GerontologybusinessAlgorithmAlgorithmsAging clinical and experimental research
researchProduct

2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint

2021

Abstract Background Since 2014, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide. Aim Based on this document, a Southeast Asia Working Group (SEAWG) wished to see how the new ESCEO algorithm developed in 2019 was perceived by Southeast Asian experts and how it was integrated into their clinical practice. Methods A SEAWG was set up between members of the international ESCEO task force and a group of Southeast Asian experts. Results Non-pharmacological management should always be combined with pharmacological management. In step 1, symptoma…

AgingSymptomatic slow-acting drugs for osteoarthritisPharmacological managementOsteoarthritisSoutheast asianSoutheast asia03 medical and health sciences0302 clinical medicineMedicine and Health SciencesHumansMedicine030212 general & internal medicineLimited evidenceConsensus DocumentReimbursement030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis KneeKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithmmedicine.diseaseAlgorithmClinical PracticeGeriatrics and GerontologybusinessAlgorithmAlgorithms
researchProduct

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis

2020

Abstract Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases. Fingolimod is an agonist of sphingosine-1-phosphate (S1P) receptors. Its main pharmacologic effect is immunomodulation by lymphocyte homing, thereby reducing the numbers of T and B cells in circulation. Because of the ubiquitous expression of S1P receptors, other effects have also been described. Here, we review preclinical experiments evaluating the effects of treatment with fingolimod in neurodegenerative diseases other than MS, such as Alzheimer’s disease or epilepsy. Fingolimo…

AgonistSphingosine 1 Phosphate Receptor ModulatorsMultiple Sclerosismedicine.drug_classDrug Evaluation PreclinicalDiseaseReview ArticleRM1-950PharmacologyNeuroprotection03 medical and health sciencesEpilepsyMice0302 clinical medicineNeurotrophic factorsAlzheimer DiseasemedicineAnimalsHumansLymphocytes030304 developmental biologyPharmacology0303 health sciencesEpilepsyMicrogliabusiness.industryFingolimod HydrochlorideMultiple sclerosisAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseFingolimod3. Good healthRatsDisease Models Animalmedicine.anatomical_structureNeuroprotective AgentsTherapeutics. PharmacologyNervous System Diseasesbusiness030217 neurology & neurosurgerymedicine.drugDrugs in R&D
researchProduct

Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

2015

Abstract The objective of this paper is to apply a previously developed semi-physiologic pharmacokinetic model implemented in NONMEM to simulate bioequivalence trials (BE) of acetyl salicylic acid (ASA) in order to validate the model performance against ASA human experimental data. ASA is a drug with first-pass hepatic and intestinal metabolism following Michaelis–Menten kinetics that leads to the formation of two main metabolites in two generations (first and second generation metabolites). The first aim was to adapt the semi-physiological model for ASA in NOMMEN using ASA pharmacokinetic parameters from literature, showing its sequential metabolism. The second aim was to validate this mod…

AnalyteChemistry PharmaceuticalMetaboliteCmaxPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalBiomarkers PharmacologicalFirst pass effectchemistry.chemical_compoundPharmacokineticsIn vivoHumansMedicineComputer SimulationTissue DistributionBiotransformationChromatographyAspirinDose-Response Relationship Drugbusiness.industryHippuratesAnti-Inflammatory Agents Non-SteroidalNONMEMDrug LiberationTherapeutic EquivalencychemistryPharmacology ClinicalSalicylic AcidbusinessAlgorithmsSoftwareEuropean Journal of Pharmaceutical Sciences
researchProduct

Cyclooxygenase inhibitors – current status and future prospects

2001

Prostaglandins are formed from arachidonic acid by the action of cyclooxygenase and subsequent downstream synthetases. Two closely related forms of the cyclooxygenase have been identified which are now known as COX-1 and COX-2. Both isoenzymes transform arachidonic acid to prostaglandins, but differ in their distribution and their physiological roles. Meanwhile, the responsible genes and their regulation have been clarified. COX-1, the pre-dominantly constitutive form of the enzyme, is expressed throughout the body and performs a number of homeostatic functions such as maintaining normal gastric mucosa and influencing renal blood flow and platelet aggregation. In contrast, the inducible for…

AngiogenesisInflammationPharmacologyStructure-Activity Relationshipchemistry.chemical_compoundIndometacinDrug DiscoverymedicineAnimalsHumansCyclooxygenase InhibitorsPharmacologyMolecular StructurebiologyAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryGeneral Medicinemedicine.diseasechemistryBiochemistryEnzyme inhibitorRheumatoid arthritisbiology.proteinArachidonic acidCyclooxygenasemedicine.symptomHomeostasisForecastingmedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Oxidative stress protection by manganese complexes of tail-tied aza-scorpiand ligands.

2015

The Mn2+ coordination chemistry of double scorpiand ligands in which two polyazacyclophane macrocycles have been connected by pyridine, phenanthroline and bipyridine spacers has been studied by potentiometry, paramagnetic NMR and electrochemistry. All ligands show high stability with Mn2+ and the complexes were formed in a wide pH range. DFT calculations support the structures and coordination geometries derived from the study. A remarkable antioxidant activity was evidenced for these systems by the McCord-Fridovich assay and in Escherichiacoli sodAsodB deficient bacterial cells. The three systems were tested as anti-inflammatory drugs in human macrophages measuring the accumulation of cyto…

AntioxidantStereochemistrymedicine.medical_treatmentPhenanthrolineInorganic chemistrychemistry.chemical_elementManganese010402 general chemistryElectrochemistry01 natural sciencesBiochemistryAntioxidantsCoordination complexInorganic ChemistrySuperoxide dismutasechemistry.chemical_compoundBipyridineBacterial ProteinsCoordination ComplexesCell Line TumorPyridinemedicineEscherichia coliHumanschemistry.chemical_classificationManganesebiology010405 organic chemistryChemistrySuperoxide DismutaseMacrophagesAnti-Inflammatory Agents Non-Steroidal0104 chemical sciencesOxidative Stressbiology.proteinJournal of inorganic biochemistry
researchProduct

Alzheimer’s disease and genetics of inflammation: a pharmacogenomic vision

2007

Inflammation plays a key role in Alzheimer disease, and dissecting the genetics of inflammation may provide an answer to the possible treatment. The next-generation therapy is based on a pharmacogenomics that will reconure new approaches to a drug used on definite people with specific dosage. The translation of pharmacogenomics into clinical practice will allow bold steps to be taken toward personalized medicine. In response to tissue injury elicited by trauma or infection, the inflammatory response sets in as a complex network of molecular and cellular interactions, directed to facilitate a return to physiological homeostasis and tissue repair. The role of an individual’s genetic backgroun…

Apolipoprotein E2alzheimerInflammationDiseaseAlzheimer DiseaseGeneticsHumansMedicineSettore MED/05 - Patologia ClinicaClinical significancePhysiological HomeostasisInflammationPharmacologyGeneticsSettore MED/04 - Patologia Generalebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseToll-Like Receptor 4PharmacogeneticsPharmacogenomicsTLR4CytokinesMolecular MedicinePersonalized medicinemedicine.symptomAlzheimer's diseasebusiness
researchProduct